Form 4: Immunome Director James P. Boylan Acquires Stock Options

Director James P. Boylan acquired stock options in Immunome Inc. on June 13, 2024, but disclaims beneficial ownership due to an agreement with Enavate Sciences, LP.

Summary

• James P. Boylan, a director of Immunome Inc., acquired 11,333 stock options on June 13, 2024.
• The exercise price of these options is $16.04.
• The options vest in four quarterly installments starting June 13, 2024, and expire on June 12, 2034.
• Boylan has agreed to hold any securities granted to him for his service as a director for the benefit of Enavate Sciences, LP, and disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a stock option grant. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The options vest in four quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

Management Comments

• Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors.
• Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities.

Industry Context

This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and compensate board members.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotechnology industry, often used to align the interests of board members with those of shareholders.
• The vesting schedule of quarterly installments over one year is a typical arrangement for such grants.
• Similar grants can be seen at companies like Amgen (AMGN) and Regeneron (REGN), where directors receive equity compensation as part of their overall remuneration.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to act in the best interests of the shareholders.
• The arrangement with Enavate Sciences, LP, may be of interest to stakeholders, as it clarifies the beneficial ownership of the securities.

Key Dates